Novocure to Present Late-Breaking Phase 3 PANOVA-3 Data for TTFields in Pancreatic Cancer at ASCO 2025
Novocure, a global leader in innovative cancer treatments, has announced that it will present additional data from its pivotal Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy at the highly anticipated 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation will take place during the conference, which is scheduled for May 30 to June 3 in Chicago, Illinois. This data represents an important milestone in the clinical development of TTFields for the treatment of pancreatic cancer, a disease with notoriously poor prognosis and limited treatment options.
The PANOVA-3 trial is one of the most significant studies in Novocure’s history, and the data presented at ASCO could have profound implications for the treatment of patients with pancreatic cancer. The study investigated the combination of TTFields therapy with gemcitabine and nab-paclitaxel, two chemotherapy agents that are commonly used in the treatment of locally advanced pancreatic adenocarcinoma. These results are particularly noteworthy given the difficult-to-treat nature of this cancer, which is often diagnosed at an advanced stage and is frequently resistant to conventional treatments.
PANOVA-3 Trial Details
The PANOVA-3 trial was a large, multi-center, randomized, open-label study that sought to evaluate the safety and efficacy of TTFields therapy when used in combination with gemcitabine and nab-paclitaxel. The trial enrolled patients with unresectable, locally advanced pancreatic adenocarcinoma (LA-PAC), a particularly challenging form of pancreatic cancer that cannot be surgically removed and typically has a poor prognosis.
Novocure’s TTFields therapy, which uses electric fields to disrupt the process of cell division, was tested as an adjunct to standard chemotherapy treatment. The primary endpoint of the trial was to assess the impact of TTFields on overall survival (OS) in patients receiving the combination therapy. According to Novocure’s prior announcement, the PANOVA-3 trial achieved its primary endpoint, showing a statistically significant improvement in median overall survival in patients treated with TTFields therapy in addition to the chemotherapy regimen, as compared to those who received chemotherapy alone.
These results are highly significant because pancreatic cancer is notoriously resistant to treatment, and improving overall survival is a critical milestone in the search for more effective therapies. Current treatment options for pancreatic cancer are limited, and the improvement in overall survival demonstrated by the PANOVA-3 trial marks a promising step forward for patients facing this devastating disease.
Oral Presentation at ASCO
The latest data from the PANOVA-3 trial will be presented in a Late Breaking Abstract session at the 2025 ASCO Annual Meeting. The session, entitled “PANOVA-3: Phase 3 Study of Tumor Treating Fields (TTFields) with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Ductal Adenocarcinoma (LA-PAC),” will feature Dr. Vincent Picozzi, MD, the principal investigator of the trial, as the presenting author. The presentation will take place on May 31, 2025, from 3:00 to 6:00 PM CDT.
Dr. Picozzi, a leading expert in pancreatic cancer and a principal investigator in several clinical trials, will provide in-depth insights into the trial design, patient population, treatment regimen, and the promising results achieved in the study. This presentation will be a key opportunity for oncologists, researchers, and healthcare professionals attending ASCO to learn more about the potential role of TTFields therapy in treating pancreatic cancer, particularly in combination with chemotherapy.
The Late Breaking Abstract session at ASCO is a prestigious platform for presenting the most compelling and novel findings in oncology, and the inclusion of PANOVA-3 data underscores the growing interest in TTFields therapy as an adjunct to conventional cancer treatments. The session will provide attendees with an opportunity to delve into the specifics of the trial’s outcomes and the potential clinical implications of these findings.
Novocure’s Commitment to Pancreatic Cancer
Novocure’s ongoing research into the use of TTFields for pancreatic cancer is part of the company’s broader mission to improve outcomes for patients with hard-to-treat cancers. With an innovative approach that differs from traditional chemotherapy and radiation, TTFields therapy offers a promising new option for patients battling cancer.
As part of its commitment to advancing the treatment of pancreatic cancer, Novocure is also dedicated to exploring how its TTFields technology can be integrated into existing treatment regimens to enhance the efficacy of chemotherapy. The company’s research into the combination of TTFields therapy with chemotherapy agents such as gemcitabine and nab-paclitaxel reflects a strategic focus on providing patients with more effective, less toxic options.
The results of the PANOVA-3 trial have the potential to open new therapeutic avenues for patients with pancreatic cancer, and Novocure’s continued work in this area is expected to contribute significantly to the ongoing fight against this challenging disease.
Investor Event Following ASCO Presentation
Following the oral presentation at the ASCO Annual Meeting, Novocure will host a special investor event to discuss the results in greater detail. The event will feature Dr. Vincent Picozzi, the principal investigator of the PANOVA-3 trial, alongside Novocure leadership, who will provide additional insights into the trial’s findings and their implications for the future of pancreatic cancer treatment. The event will be an opportunity for investors, analysts, and other stakeholders to engage directly with the company’s leadership and ask questions about the data presented at ASCO.
This investor event comes at a pivotal moment for Novocure, as the company is poised to expand the clinical use of TTFields therapy across a variety of cancer indications. The PANOVA-3 trial results will likely be a key topic of discussion, with investors eager to understand how this data might influence the company’s future growth prospects and its potential to transform the treatment landscape for pancreatic cancer and beyond.
The Future of TTFields Therapy
As Novocure prepares to showcase its promising PANOVA-3 trial results at ASCO, the company’s work in the field of cancer treatment is only just beginning to gain widespread attention. TTFields therapy, which has already shown promise in the treatment of various cancer types, including glioblastoma, non-small cell lung cancer, and ovarian cancer, could represent a new frontier in the battle against pancreatic cancer.
With the results of the PANOVA-3 trial expected to further validate the efficacy of TTFields therapy in combination with chemotherapy, Novocure is on the cusp of making a significant impact on the treatment of pancreatic cancer. The company’s commitment to innovation and patient-centered care positions it as a leader in the development of novel cancer therapies, and the upcoming ASCO presentation will likely be a defining moment in its journey.
For those attending the 2025 ASCO Annual Meeting, Novocure’s presentation of the PANOVA-3 trial data is expected to be one of the highlights of the conference, offering exciting new possibilities for the treatment of pancreatic cancer. As the field of oncology continues to evolve, Novocure’s groundbreaking research in TTFields therapy is helping to pave the way for more effective, less invasive cancer treatments.
In conclusion, Novocure’s ongoing work with TTFields therapy in pancreatic cancer is a testament to the company’s commitment to improving patient outcomes through innovation. The PANOVA-3 trial results represent a promising step forward in the quest to improve survival for patients with pancreatic cancer, and the upcoming ASCO presentation will no doubt serve as a pivotal moment in the advancement of this cutting-edge therapy.
